Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Overview of attention for article published in Lancet Oncology, January 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

news: 7 news outlets
blogs: 1 blog
twitter: 27 X users

patent: 2 patents
guideline: 3 clinical guideline sources
podcasts: 1 podcast

Readers on

mendeley: 109 Mendeley

So far, Altmetric has seen 8 news stories from 7 outlets.

Erdafitinib or Chemotherapy in Advanced Pre-Treated Urothelial Carcinoma | 2 Minute Medicine

2 Minute Medicine , 27 Nov 2023

1. The median overall survival was 12.1 months in the erdafitinib group and 7.8 months in the chemotherapy group, with an HR of…

FGFR Inhibitor Stakes Claim to Post-Anti-PD-1 Role in Advanced Bladder Cancer

MedPage Today, 07 Jun 2023

Meeting Coverage > ASCO Survival benefit supports FGFR testing for all patients with metastatic disease, researcher says by…

An Influx of Data Expands Options, Improves Treatment for Bladder Cancer

OncLive, 18 Oct 2022

The past decade has seen a change in the tide for patients with bladder cancer with the introduction of checkpoint blockade and…

Erdafitinib Yields Durable Responses in Advanced Urothelial Carcinoma

Renal & Urology News, 14 Feb 2022

Erdafitinib demonstrated durable activity in patients with locally advanced or metastatic urothelial carcinoma with specific…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 4 additional news stories.